AKT1 and hepatocellular carcinoma: Wu found upregulation of MK-STYX in HCC, along with downregulation of the RNA-binding protein, CELF2, through the PI3K/Akt pathway which accelerated HCC proliferation and inhibited apoptosis, thereby promoting the malignant progression of HCC (67).